PMID- 20571352
OWN - NLM
STAT- MEDLINE
DCOM- 20100830
LR  - 20181201
IS  - 1538-2990 (Electronic)
IS  - 0002-9629 (Linking)
VI  - 340
IP  - 2
DP  - 2010 Aug
TI  - Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
PG  - 133-43
LID - 10.1097/MAJ.0b013e3181d64344 [doi]
AB  - Successful management of type 2 diabetes mellitus (T2DM) requires attention to 
      additional conditions often associated with hyperglycemia including overweight or 
      obesity, dyslipidemia and hypertension, as each has some relationship with 
      microvascular or macrovascular complications. Because control of cardiovascular 
      risk factors is as important as glucose control in T2DM, these risk factors need 
      to be addressed, and it is critical that antidiabetes medications do not 
      exacerbate these risk factors. A patient-centered approach to treatment in which 
      clinicians maximize patient involvement in the selection of antidiabetes therapy 
      may lead to increased adherence and improved clinical outcomes. The incretin 
      hormones, which include glucagon-like peptide-1 (GLP-1), are involved in 
      glucoregulation and have become an important focus of T2DM research and 
      treatment. Incretin-based therapies, such as the glucagon-like peptide-1 receptor 
      agonists and the dipeptidyl peptidase-IV inhibitors, have shown beneficial 
      effects on hyperglycemia, weight, blood pressure and lipids with a low incidence 
      of hypoglycemia.
FAU - Kuritzky, Louis
AU  - Kuritzky L
AD  - University of Florida College of Medicine, Gainesville, 32601, USA. 
      lkuritzky@aol.com
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Am J Med Sci
JT  - The American journal of the medical sciences
JID - 0370506
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptides)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Nitriles)
RN  - 0 (Peptides)
RN  - 0 (Piperidines)
RN  - 0 (Pyrazines)
RN  - 0 (Pyrrolidines)
RN  - 0 (Triazoles)
RN  - 0 (Venoms)
RN  - 2PHK27IP3B (taspoglutide)
RN  - 56HH86ZVCT (Uracil)
RN  - 5E7U48495E (rGLP-1 protein)
RN  - 839I73S42A (Liraglutide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9GB927LAJW (saxagliptin)
RN  - 9P1872D4OL (Exenatide)
RN  - I6B4B2U96P (Vildagliptin)
RN  - JHC049LO86 (alogliptin)
RN  - PJY633525U (Adamantane)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
SB  - IM
MH  - Adamantane/analogs & derivatives/therapeutic use
MH  - Blood Glucose/metabolism
MH  - Diabetes Mellitus, Type 2/drug therapy/*therapy
MH  - Dipeptides/therapeutic use
MH  - Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - Exenatide
MH  - Glucagon-Like Peptide 1/analogs & derivatives/therapeutic use
MH  - Humans
MH  - Hyperglycemia/drug therapy/therapy
MH  - Hypoglycemic Agents/administration & dosage/therapeutic use
MH  - Liraglutide
MH  - Nitriles/therapeutic use
MH  - Obesity/therapy
MH  - Patient Compliance
MH  - Peptides/administration & dosage/therapeutic use
MH  - Piperidines/therapeutic use
MH  - Precision Medicine
MH  - Primary Health Care
MH  - Pyrazines/therapeutic use
MH  - Pyrrolidines/therapeutic use
MH  - Risk Factors
MH  - Sitagliptin Phosphate
MH  - Triazoles/therapeutic use
MH  - Uracil/analogs & derivatives/therapeutic use
MH  - Venoms/administration & dosage/therapeutic use
MH  - Vildagliptin
RF  - 71
EDAT- 2010/06/24 06:00
MHDA- 2010/08/31 06:00
CRDT- 2010/06/24 06:00
PHST- 2010/06/24 06:00 [entrez]
PHST- 2010/06/24 06:00 [pubmed]
PHST- 2010/08/31 06:00 [medline]
AID - S0002-9629(15)31519-6 [pii]
AID - 10.1097/MAJ.0b013e3181d64344 [doi]
PST - ppublish
SO  - Am J Med Sci. 2010 Aug;340(2):133-43. doi: 10.1097/MAJ.0b013e3181d64344.